Article
Oncology
Hidekiyo Yamaki, Michihisa Kono, Risa Wakisaka, Hiroki Komatsuda, Takumi Kumai, Ryusuke Hayashi, Ryosuke Sato, Toshihiro Nagato, Takayuki Ohkuri, Akemi Kosaka, Kenzo Ohara, Kan Kishibe, Miki Takahara, Tatsuya Hayashi, Hiroya Kobayashi, Akihiro Katada
Summary: Brachyury is a transcription factor involved in mesoderm formation and differentiation, and its overexpression is associated with poor prognosis in many cancers. This study identified antigenic peptide segments derived from Brachyury that can induce tumor-reactive T cells. Combination therapy using PD-1/PD-L1 blockade and GEM enhances the tumor-reactivity of Brachyury-reactive T cells. These findings suggest that immunotherapy targeting Brachyury with peptide, GEM, and immune checkpoint blockade holds promise for the treatment of head and neck cancer.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Chisato Yokota, Naoki Kagawa, Koji Takano, Yasuyoshi Chiba, Manabu Kinoshita, Noriyuki Kijima, Yusuke Oji, Yoshihiro Oka, Haruo Sugiyama, Akihiro Tsuboi, Shuichi Izumoto, Haruhiko Kishima, Naoya Hashimoto
Summary: This study found that WT1 and HLA class I antigen expression in tumor cells significantly decreased after WT1 peptide vaccine treatment, and maintenance of WT1 expression during vaccination was associated with longer survival. High HLA class I antigen expression and low CD4(+)/CD8(+) TIL ratio in pre-vaccination samples were also linked to better outcomes. The number of infiltrating CD4(+) T cells decreased post-vaccination, providing insights into immune reactions during cancer immunotherapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Immunology
Zheling Chen, Shanshan Zhang, Ning Han, Jiahong Jiang, Yunyun Xu, Dongying Ma, Lantian Lu, Xiaojie Guo, Min Qiu, Qinxue Huang, Huimin Wang, Fan Mo, Shuqing Chen, Liu Yang
Summary: This study enrolled 7 advanced pancreatic cancer patients and successfully applied neoantigen identification and selection, demonstrating that a personalized neoantigen-based peptide vaccine iNeo-Vac-P01 could improve the clinical efficacy limitations of pancreatic cancer.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Shouq Alzaaqi, Norifumi Naka, Kenichiro Hamada, Naoki Hosen, Mizuki Kanegae, Hidetatsu Outani, Mayuko Adachi, Rin Imanishi, Eiichi Morii, Miki Iwai, Jun Nakata, Fumihiro Fujiki, Soyoko Morimoto, Hiroko Nakajima, Sumiyuki Nishida, Akihiro Tsuboi, Yoshihiro Oka, Haruo Sugiyama, Yusuke Oji
Summary: This study investigated the immune response to peptide-based cancer vaccines targeting the WT1 tumor gene in patients with advanced sarcoma. The results showed that immune recognition of the WT1 antigen existed prior to vaccine administration, and specific antibodies could be used as immune-monitoring markers.
Editorial Material
Urology & Nephrology
Angelena Edwards, Niccolo M. Passoni, Rebecca Collins, Smitha Vidi, Jyothsna Gattineni, Linda A. Baker
Summary: This case study describes a term infant with 46, XY Denys-Drash syndrome who underwent peritoneal dialysis and surgical treatment for renal abnormalities without the use of chemotherapy.
Article
Oncology
Hiroko Nakajima, Jun Nakata, Kanako Imafuku, Hiromu Hayashibara, Kazuki Isokawa, Keiko Udaka, Fumihiro Fujiki, Soyoko Morimoto, Kana Hasegawa, Naoki Hosen, Yoshiko Hashii, Sumiyuki Nishida, Akihiro Tsuboi, Yoshihiro Oka, Yusuke Oji, Shinji Sogo, Haruo Sugiyama
Summary: This study identified three novel mouse Th epitope peptides that strongly induced and maintained WT1-specific CTLs, efficiently rejected WT1-expressing tumor cells, and showed that these CTLs played a central role in tumor rejection. The majority of WT1-specific CTLs induced by the co-immunization with WT1 CTL and the WT1-specific Th peptides were effector memory CD8(+) T cells, demonstrating their essential function in WT1-specific tumor immunity.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Yasunori Ueda, Kensuke Usuki, Jiro Fujita, Itaru Matsumura, Nobuyuki Aotsuka, Naohiro Sekiguchi, Tomonori Nakazato, Hiromi Iwasaki, Mariko Takahara-Matsubara, Saori Sugimoto, Masashi Goto, Tomoki Naoe, Masahiro Kizaki, Yasushi Miyazaki, Koichi Aakashi
Summary: DSP-7888, an immunotherapeutic cancer vaccine derived from WT1 protein, showed acceptable safety and clinical activity in patients with MDS. Patients with a WT1-specific immune response had longer survival.
Review
Cell Biology
Alica K. Beutel, Christopher J. Halbrook
Summary: Pancreatic ductal adenocarcinoma (PDA) is a leading cause of cancer-related deaths worldwide and its treatment is challenging due to a lack of durable responses to standard-of-care chemotherapies. Gemcitabine, a cornerstone in PDA treatment, faces resistance mechanisms that have not yet been overcome in patient care.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Sung Yoon Cho, Seong Mun Jeong, Young Joo Jeon, Sun Ja Yang, Ju Eun Hwang, Byung Moo Yoo, Hyun Soo Kim
Summary: Dendritic cells (DC) are powerful cells in anti-tumor immunity, and their use in cancer immunotherapy unlocks hidden capabilities as an effective therapeutic.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Siqing Fu, David E. Piccioni, Hongtao Liu, Rimas Lukas, Santosh Kesari, Dawit Aregawi, David S. Hong, Kenichiro Yamaguchi, Kate Whicher, Yi Zhang, Yu-Luan Chen, Nagaraju Poola, John Eddy, David Blum
Summary: WT2725 is a WT1-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1(+) tumors in patients with HLA-A*0201(+) and/or HLA-A*0206(+). The phase I study showed that WT2725 dosing emulsion was well tolerated, with promising antitumor activity in malignancies known to overexpress the WT1 protein, especially in glioblastoma patients.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Fumihiro Fujiki, Akihiro Tsuboi, Soyoko Morimoto, Naoya Hashimoto, Miki Inatome, Hiroko Nakajima, Jun Nakata, Sumiyuki Nishida, Kana Hasegawa, Naoki Hosen, Yoshihiro Oka, Yusuke Oji, Shinji Sogo, Haruo Sugiyama
Summary: The study showed a stronger induction of WT1-specific CTLs in patients who received WT1 CTL + WT1 helper peptide vaccine compared to those who received WT1 CTL vaccine alone. Importantly, a clear correlation was demonstrated between WT1-specific CTL and WT1(332)-specific HTL responses.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Immunology
Si-Yuan Zhu, Ke-Da Yu
Summary: Breast cancer is the most commonly diagnosed cancer worldwide, with relapse and metastasis posing significant challenges. Innovative therapeutic strategies, such as cancer vaccines, are needed to address these challenges. Although current results have been disappointing, recent studies suggest the potential of combining vaccines with other treatments for breast cancer.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Engineering, Biomedical
Afeng Yang, Yun Bai, Xia Dong, Teng Ma, Dunwan Zhu, Lin Mei, Feng Lv
Summary: The biomaterial-mediated combined cell vaccines provide an innovative strategy for cancer immunotherapy by combining tumor cell and DC vaccines with a hydrogel and nanoadjuvant. This approach enhances the immunogenicity of cell vaccines, promotes antigen presentation, and inhibits tumor growth effectively, showing promising potential for improving cancer immunotherapy.
ACTA BIOMATERIALIA
(2021)
Article
Medical Laboratory Technology
Faliang Wang, Jiabin Cai, Jinhu Wang, Min He, Junqing Mao, Kun Zhu, Manli Zhao, Zhonghai Guan, Linjie Li, Hongchuan Jin, Qiang Shu
Summary: The study identified a case of Denys-Drash syndrome with an uncommon missense mutation in the WT1 gene, which may serve as a crucial marker in DDS. The mutated variant showed a weaker effect in inhibiting tumor cells compared to the wild-type WT1.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2021)
Article
Oncology
Brigitte Royer-Pokora, Maike Anna Busch, Sarah Tenbusch, Mathias Schmidt, Manfred Beier, Andrew D. Woods, Holger Thiele, Jaume Mora
Summary: Wilms tumors are childhood kidney tumors that are heterogeneous with distinct subgroups, including a subtype associated with WT1 gene mutations. Researchers have successfully established 11 cell lines from the WT1 mutant subtype, providing a valuable tool for studying the biology and genetics of this specific type of Wilms tumor. These cell lines may lead to new approaches in treatment development.
